ID   GLCM_HUMAN              Reviewed;         536 AA.
AC   P04062; A8K796; Q16545; Q4VX22; Q6I9R6; Q9UMJ8;
DT   01-NOV-1986, integrated into UniProtKB/Swiss-Prot.
DT   09-NOV-2004, sequence version 3.
DT   21-MAR-2012, entry version 160.
DE   RecName: Full=Glucosylceramidase;
DE            EC=3.2.1.45;
DE   AltName: Full=Acid beta-glucosidase;
DE   AltName: Full=Alglucerase;
DE   AltName: Full=Beta-glucocerebrosidase;
DE   AltName: Full=D-glucosyl-N-acylsphingosine glucohydrolase;
DE   AltName: Full=Imiglucerase;
DE   Flags: Precursor;
GN   Name=GBA; Synonyms=GC, GLUC;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RC   TISSUE=Placenta;
RX   MEDLINE=86042651; PubMed=3864160; DOI=10.1073/pnas.82.21.7289;
RA   Sorge J., West C., Westwood B., Beutler E.;
RT   "Molecular cloning and nucleotide sequence of human glucocerebrosidase
RT   cDNA.";
RL   Proc. Natl. Acad. Sci. U.S.A. 82:7289-7293(1985).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND VARIANT LEU-298.
RC   TISSUE=Hepatoma;
RX   MEDLINE=86085859; PubMed=3001061;
RA   Tsuji S., Choudary P.V., Martin B.M., Winfield S., Barranger J.A.,
RA   Ginns E.I.;
RT   "Nucleotide sequence of cDNA containing the complete coding sequence
RT   for human lysosomal glucocerebrosidase.";
RL   J. Biol. Chem. 261:50-53(1986).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Liver;
RX   MEDLINE=89122038; PubMed=2914709; DOI=10.1016/0888-7543(89)90319-4;
RA   Horowitz M., Wilder S., Horowitz Z., Reiner O., Gelbart T.,
RA   Beutler E.;
RT   "The human glucocerebrosidase gene and pseudogene: structure and
RT   evolution.";
RL   Genomics 4:87-96(1989).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Liver;
RX   MEDLINE=92241881; PubMed=1572652; DOI=10.1016/0888-7543(92)90311-F;
RA   Beutler E., West C., Gelbart T.;
RT   "Polymorphisms in the human glucocerebrosidase gene.";
RL   Genomics 12:795-800(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG AND 3), VARIANTS GD ARG-223;
RP   GLY-230; PRO-235; ARG-241; ILE-252 AND ARG-364, AND VARIANTS GLY-310
RP   AND HIS-368.
RX   MEDLINE=94124033; PubMed=8294033; DOI=10.1016/0378-1119(93)90497-Q;
RA   Imai K., Nakamura M., Yamada M., Asano A., Yokoyama S., Tsuji S.,
RA   Ginns E.I.;
RT   "A novel transcript from a pseudogene for human glucocerebrosidase in
RT   non-Gaucher disease cells.";
RL   Gene 136:365-368(1993).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   MEDLINE=97474796; PubMed=9331372;
RA   Winfield S.L., Tayebi N., Martin B.M., Ginns E.I., Sidransky E.;
RT   "Identification of three additional genes contiguous to the
RT   glucocerebrosidase locus on chromosome 1q21: implications for Gaucher
RT   disease.";
RL   Genome Res. 7:1020-1026(1997).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 1-11.
RX   MEDLINE=88195776; PubMed=3359914;
RA   Reiner O., Wigderson M., Horowitz M.;
RT   "Structural analysis of the human glucocerebrosidase genes.";
RL   DNA 7:107-116(1988).
RN   [11]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-45.
RX   MEDLINE=88074307; PubMed=3687939;
RA   Sorge J.A., West C., Kuhl W., Treger L., Beutler E.;
RT   "The human glucocerebrosidase gene has two functional ATG initiator
RT   codons.";
RL   Am. J. Hum. Genet. 41:1016-1024(1987).
RN   [12]
RP   PROTEIN SEQUENCE OF 40-44.
RC   TISSUE=Placenta;
RA   Martin B.M., Murray G.J., Coligan J.E., Raum M., Brady R.O.,
RA   Barranger J.A.;
RT   "Sturctural studies of human placental glucocerebrosidase.";
RL   Fed. Proc. 43:1869-1869(1984).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 403-416.
RX   MEDLINE=85022513; PubMed=6091633;
RA   Ginns E.I., Choudary P.V., Martin B.M., Winfield S., Stubblefield B.,
RA   Mayor J., Merkle-Lehman D., Murray G.J., Bowers L.A., Barranger J.A.;
RT   "Isolation of cDNA clones for human beta-glucocerebrosidase using the
RT   lambda gt11 expression system.";
RL   Biochem. Biophys. Res. Commun. 123:574-580(1984).
RN   [14]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 409-462, AND VARIANT GD1 SER-409.
RC   TISSUE=Skin;
RA   Tsuji S., Martin B.M., Barranger J.A., Stubblefield B.K.,
RA   LaMarca M.E., Ginns E.I.;
RT   "Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes
RT   in Ashkenazic and non-Ashkenazic individuals.";
RL   Proc. Natl. Acad. Sci. U.S.A. 85:2349-2352(1988).
RN   [15]
RP   PROTEIN SEQUENCE OF 469-520.
RC   TISSUE=Placenta;
RX   MEDLINE=86149363; PubMed=3456607; DOI=10.1073/pnas.83.6.1660;
RA   Dinur T., Osiecki K.M., Legler G., Gatt S., Desnick R.J.,
RA   Grabowski G.A.;
RT   "Human acid beta-glucosidase: isolation and amino acid sequence of a
RT   peptide containing the catalytic site.";
RL   Proc. Natl. Acad. Sci. U.S.A. 83:1660-1664(1986).
RN   [16]
RP   MASS SPECTROMETRY, MUTAGENESIS OF GLU-379, AND ACTIVE SITE.
RX   PubMed=7908905;
RA   Miao S., McCarter J.D., Grace M.E., Grabowski G.A., Aebersold R.,
RA   Withers S.G.;
RT   "Identification of Glu340 as the active-site nucleophile in human
RT   glucocerebrosidase by use of electrospray tandem mass spectrometry.";
RL   J. Biol. Chem. 269:10975-10978(1994).
RN   [17]
RP   INTERACTION WITH SAPOSIN-C AND MEMBRANES CONTAINING ANIONIC
RP   PHOSPHOLIPIDS.
RX   PubMed=10781797; DOI=10.1016/S0014-5793(00)01417-4;
RA   Salvioli R., Tatti M., Ciaffoni F., Vaccaro A.M.;
RT   "Further studies on the reconstitution of glucosylceramidase activity
RT   by Sap C and anionic phospholipids.";
RL   FEBS Lett. 472:17-21(2000).
RN   [18]
RP   GLYCOSYLATION AT ASN-98; ASN-185 AND ASN-309.
RX   MEDLINE=22660472; PubMed=12754519; DOI=10.1038/nbt827;
RA   Zhang H., Li X.-J., Martin D.B., Aebersold R.;
RT   "Identification and quantification of N-linked glycoproteins using
RT   hydrazide chemistry, stable isotope labeling and mass spectrometry.";
RL   Nat. Biotechnol. 21:660-666(2003).
RN   [19]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH SCARB2.
RX   PubMed=18022370; DOI=10.1016/j.cell.2007.10.018;
RA   Reczek D., Schwake M., Schroder J., Hughes H., Blanz J., Jin X.,
RA   Brondyk W., Van Patten S., Edmunds T., Saftig P.;
RT   "LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent
RT   targeting of beta-glucocerebrosidase.";
RL   Cell 131:770-783(2007).
RN   [20]
RP   SUBCELLULAR LOCATION [LARGE SCALE ANALYSIS], AND MASS SPECTROMETRY.
RC   TISSUE=Placenta;
RX   PubMed=17897319; DOI=10.1111/j.1600-0854.2007.00643.x;
RA   Schroeder B., Wrocklage C., Pan C., Jaeger R., Koesters B.,
RA   Schaefer H., Elsaesser H.-P., Mann M., Hasilik A.;
RT   "Integral and associated lysosomal membrane proteins.";
RL   Traffic 8:1676-1686(2007).
RN   [21]
RP   INVOLVEMENT IN PARKINSON DISEASE, AND VARIANTS GLU-46; CYS-170;
RP   GLU-232; GLN-296; SER-409; ALA-419; HIS-448; ASN-482; PRO-483;
RP   PRO-495; LEU-497 AND CYS-502.
RX   PubMed=19286695; DOI=10.1093/brain/awp044;
RA   Neumann J., Bras J., Deas E., O'Sullivan S.S., Parkkinen L.,
RA   Lachmann R.H., Li A., Holton J., Guerreiro R., Paudel R., Segarane B.,
RA   Singleton A., Lees A., Hardy J., Houlden H., Revesz T., Wood N.W.;
RT   "Glucocerebrosidase mutations in clinical and pathologically proven
RT   Parkinson's disease.";
RL   Brain 132:1783-1794(2009).
RN   [22]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-98 AND ASN-309, AND MASS
RP   SPECTROMETRY.
RC   TISSUE=Liver;
RX   PubMed=19159218; DOI=10.1021/pr8008012;
RA   Chen R., Jiang X., Sun D., Han G., Wang F., Ye M., Wang L., Zou H.;
RT   "Glycoproteomics analysis of human liver tissue by combination of
RT   multiple enzyme digestion and hydrazide chemistry.";
RL   J. Proteome Res. 8:651-661(2009).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 40-536, GLYCOSYLATION AT
RP   ASN-58, AND DISULFIDE BONDS.
RX   PubMed=12792654; DOI=10.1038/sj.embor.embor873;
RA   Dvir H., Harel M., McCarthy A.A., Toker L., Silman I., Futerman A.H.,
RA   Sussman J.L.;
RT   "X-ray structure of human acid-beta-glucosidase, the defective enzyme
RT   in Gaucher disease.";
RL   EMBO Rep. 4:704-709(2003).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 40-536 IN COMPLEX WITH
RP   SYNTHETIC INHIBITOR, AND ACTIVE SITE.
RX   PubMed=15817452; DOI=10.1074/jbc.M502799200;
RA   Premkumar L., Sawkar A.R., Boldin-Adamsky S., Toker L., Silman I.,
RA   Kelly J.W., Futerman A.H., Sussman J.L.;
RT   "X-ray structure of human acid-beta-glucosidase covalently bound to
RT   conduritol-B-epoxide. Implications for Gaucher disease.";
RL   J. Biol. Chem. 280:23815-23819(2005).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 40-536, CHARACTERIZATION OF
RP   VARIANTS GD SER-55; GLN-87; ASN-118; GLN-159; LEU-161; VAL-162;
RP   VAL-166; ASN-200; PHE-213; PHE-224; GLU-232; GLU-237; LEU-298;
RP   ILE-303; CYS-343; ILE-362; LYS-365; GLY-381; LYS-388; TRP-392;
RP   CYS-402; SER-409; VAL-410; HIS-419; LYS-421; ARG-429; LEU-433;
RP   SER-436; ASN-438; HIS-448; VAL-455; PRO-483; PRO-500 AND PRO-502, AND
RP   MUTAGENESIS OF CYS-43; CYS-57 AND CYS-62.
RX   PubMed=16293621; DOI=10.1074/jbc.M511110200;
RA   Liou B., Kazimierczuk A., Zhang M., Scott C.R., Hegde R.S.,
RA   Grabowski G.A.;
RT   "Analyses of variant acid beta-glucosidases: effects of Gaucher
RT   disease mutations.";
RL   J. Biol. Chem. 281:4242-4253(2006).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.9 ANGSTROMS) OF 40-536, AND GLYCOSYLATION AT
RP   ASN-58; ASN-98 AND ASN-185.
RX   PubMed=17139081; DOI=10.1107/S0907444906038303;
RA   Brumshtein B., Wormald M.R., Silman I., Futerman A.H., Sussman J.L.;
RT   "Structural comparison of differently glycosylated forms of acid-beta-
RT   glucosidase, the defective enzyme in Gaucher disease.";
RL   Acta Crystallogr. D 62:1458-1465(2006).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.8 ANGSTROMS) OF 40-536 IN COMPLEXES WITH
RP   ISOFAGOMINE, AND SUBCELLULAR LOCATION.
RX   PubMed=17187079; DOI=10.1038/nchembio850;
RA   Lieberman R.L., Wustman B.A., Huertas P., Powe A.C. Jr., Pine C.W.,
RA   Khanna R., Schlossmacher M.G., Ringe D., Petsko G.A.;
RT   "Structure of acid beta-glucosidase with pharmacological chaperone
RT   provides insight into Gaucher disease.";
RL   Nat. Chem. Biol. 3:101-107(2007).
RN   [29]
RP   REVIEW ON GD VARIANTS.
RX   MEDLINE=94163182; PubMed=8118460; DOI=10.1002/humu.1380030102;
RA   Horowitz M., Zimran A.;
RT   "Mutations causing Gaucher disease.";
RL   Hum. Mutat. 3:1-11(1994).
RN   [30]
RP   REVIEW ON GD VARIANTS.
RX   MEDLINE=97044507; PubMed=8889578;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:3<207::AID-HUMU2>3.3.CO;2-5;
RA   Beutler E., Gelbart T.;
RT   "Glucocerebrosidase (Gaucher disease).";
RL   Hum. Mutat. 8:207-213(1996).
RN   [31]
RP   REVIEW ON GD VARIANTS.
RX   MEDLINE=99459154; PubMed=10527671; DOI=10.1006/mgme.1999.2918;
RA   Tayebi N., Stone D.L., Sidransky E.;
RT   "Type 2 gaucher disease: an expanding phenotype.";
RL   Mol. Genet. Metab. 68:209-219(1999).
RN   [32]
RP   REVIEW ON GD VARIANTS.
RX   MEDLINE=20115339; PubMed=10649495;
RX   DOI=10.1002/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.3.CO;2-J;
RA   Stone D.L., Tayebi N., Orvisky E., Stubblefield B., Madike V.,
RA   Sidransky E.;
RT   "Glucocerebrosidase gene mutations in patients with type 2 Gaucher
RT   disease.";
RL   Hum. Mutat. 15:181-188(2000).
RN   [33]
RP   VARIANT GD TYR-255.
RX   MEDLINE=90343254; PubMed=1974409;
RX   DOI=10.1111/j.1469-1809.1990.tb00371.x;
RA   Beutler E., Gelbart T.;
RT   "Gaucher disease associated with a unique KpnI restriction site:
RT   identification of the amino-acid substitution.";
RL   Ann. Hum. Genet. 54:149-153(1990).
RN   [34]
RP   VARIANTS GD.
RX   MEDLINE=90274868; PubMed=1972019; DOI=10.1089/dna.1990.9.233;
RA   Hong C.M., Ohashi T., Yu X.J., Weiler S., Barranger J.A.;
RT   "Sequence of two alleles responsible for Gaucher disease.";
RL   DNA Cell Biol. 9:233-241(1990).
RN   [35]
RP   VARIANTS GD.
RX   MEDLINE=93162655; PubMed=8432537; DOI=10.1006/geno.1993.1035;
RA   Beutler E., Gelbart T., West C.;
RT   "Identification of six new Gaucher disease mutations.";
RL   Genomics 15:203-205(1993).
RN   [36]
RP   VARIANT GD HIS-535.
RX   MEDLINE=94379086; PubMed=7916532; DOI=10.1002/ajmg.1320510216;
RA   Choy F.Y.M., Wei C., Applegarth D.A., McGillivray B.C.;
RT   "DNA analysis of an uncommon missense mutation in a Gaucher disease
RT   patient of Jewish-Polish-Russian descent.";
RL   Am. J. Med. Genet. 51:156-160(1994).
RN   [37]
RP   VARIANT GD ASN-438.
RX   MEDLINE=94156356; PubMed=8112750; DOI=10.1007/BF00210614;
RA   Beutler E., Gelbart T.;
RT   "Two new Gaucher disease mutations.";
RL   Hum. Genet. 93:209-210(1994).
RN   [38]
RP   VARIANTS GD SER-409 AND CYS-457.
RX   MEDLINE=94357595; PubMed=8076951; DOI=10.1007/BF00208292;
RA   Tuteja R., Tuteja N., Lilliu F., Bembi B., Galanello R., Cao A.,
RA   Baralle F.E.;
RT   "Y418C: a novel mutation in exon 9 of the glucocerebrosidase gene of a
RT   patient with Gaucher disease creates a new Bgl I site.";
RL   Hum. Genet. 94:314-315(1994).
RN   [39]
RP   VARIANTS GD ASP-215; THR-221; ARG-241; GLN-296; CYS-324; GLY-417 AND
RP   ASN-419.
RX   MEDLINE=96382740; PubMed=8790604;
RA   Beutler E., Demina A., Gelbart T.;
RT   "Glucocerebrosidase mutations in Gaucher disease.";
RL   Mol. Med. 1:82-92(1994).
RN   [40]
RP   VARIANTS GD SER-409; HIS-448; PRO-483 AND CYS-502.
RX   MEDLINE=95353281; PubMed=7627184; DOI=10.1002/humu.1380050406;
RA   Cormand B., Vilageliu L., Burguera J.M., Balcells S.,
RA   Gonzalez-Duarte R., Grinberg D., Chabas A.;
RT   "Gaucher disease in Spanish patients: analysis of eight mutations.";
RL   Hum. Mutat. 5:303-309(1995).
RN   [41]
RP   VARIANT GD SER-217.
RX   MEDLINE=95353289; PubMed=7627192; DOI=10.1002/humu.1380050414;
RA   Choy F.Y.M., Wei C.;
RT   "Identification of a new mutation (P178S) in an African-American
RT   patient with type 2 Gaucher disease.";
RL   Hum. Mutat. 5:345-347(1995).
RN   [42]
RP   VARIANTS GD SER-409; LEU-426; LEU-433 AND PRO-483.
RX   MEDLINE=97092100; PubMed=8937765;
RA   Morar B., Lane A.B.;
RT   "The molecular characterization of Gaucher disease in South Africa.";
RL   Clin. Genet. 50:78-84(1996).
RN   [43]
RP   VARIANTS GD LEU-54; GLU-85 AND SER-227.
RX   MEDLINE=96271984; PubMed=8829654;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:3<214::AID-HUMU5>3.3.CO;2-Y;
RA   Kim J.-W., Liou B.B., Lai M.-Y., Ponce E., Grabowski G.A.;
RT   "Gaucher disease: identification of three new mutations in the Korean
RT   and Chinese (Taiwanese) populations.";
RL   Hum. Mutat. 7:214-218(1996).
RN   [44]
RP   VARIANTS GD HIS-352 AND GLN-398.
RX   MEDLINE=96271993; PubMed=8829663;
RX   DOI=10.1002/(SICI)1098-1004(1996)7:3<272::AID-HUMU14>3.3.CO;2-7;
RA   Cormand B., Vilageliu L., Balcells S., Gonzalez-Duatre R., Chabas A.,
RA   Grinberg D.;
RT   "Two novel (1098insA and Y313H) and one rare (R359Q) mutations
RT   detected in exon 8 of the beta-glucocerebrosidase gene in Gaucher's
RT   disease patients.";
RL   Hum. Mutat. 7:272-274(1996).
RN   [45]
RP   VARIANT GD1 THR-435.
RX   MEDLINE=97044520; PubMed=8889591;
RX   DOI=10.1002/(SICI)1098-1004(1996)8:3<280::AID-HUMU15>3.3.CO;2-6;
RA   Amaral O., Pinto E., Fortuna M., Lacerda L., Sa Miranda M.C.;
RT   "Type 1 Gaucher disease: identification of N396T and prevalence of
RT   glucocerebrosidase mutations in the Portuguese.";
RL   Hum. Mutat. 8:280-281(1996).
RN   [46]
RP   VARIANTS GD3 LEU-437 AND ILE-530.
RX   MEDLINE=96373808; PubMed=8780099;
RA   Seeman P.J.V., Finckh U., Hoeppner J., Lakner V., Liebisch I.,
RA   Grau G., Rolfs A.;
RT   "Two new missense mutations in a non-Jewish Caucasian family with type
RT   3 Gaucher disease.";
RL   Neurology 46:1102-1107(1996).
RN   [47]
RP   VARIANTS GD LEU-414 AND THR-441.
RX   MEDLINE=97325776; PubMed=9182788;
RX   DOI=10.1002/(SICI)1096-8628(19970627)70:4<437::AID-AJMG19>3.0.CO;2-I;
RA   Cormand B., Grinberg D., Gort L., Fiumara A., Barone R., Vilageliu L.,
RA   Chabas A.;
RT   "Two new mild homozygous mutations in Gaucher disease patients:
RT   clinical signs and biochemical analyses.";
RL   Am. J. Med. Genet. 70:437-443(1997).
RN   [48]
RP   VARIANTS GD VAL-76; GLU-85; TRP-87; TRP-159; SER-227; ILE-252 AND
RP   PRO-483.
RX   MEDLINE=97360189; PubMed=9217217;
RX   DOI=10.1002/(SICI)1096-8628(19970808)71:2<172::AID-AJMG10>3.0.CO;2-B;
RA   Choy F.Y.M., Humphries M.L., Shi H.;
RT   "Identification of two novel and four uncommon missense mutations
RT   among Chinese Gaucher disease patients.";
RL   Am. J. Med. Genet. 71:172-178(1997).
RN   [49]
RP   VARIANT GD LYS-501.
RX   MEDLINE=97425095; PubMed=9279145;
RA   Hatton C.E., Cooper A., Whitehouse C., Wraith J.E.;
RT   "Mutation analysis in 46 British and Irish patients with Gaucher's
RT   disease.";
RL   Arch. Dis. Child. 77:17-22(1997).
RN   [50]
RP   VARIANTS GD TRP-87; GLU-234; ARG-241; ILE-252; ASN-310; LEU-391 AND
RP   SER-409.
RX   MEDLINE=97298149; PubMed=9153297; DOI=10.1172/JCI119437;
RA   Grace M.E., Desnick R.J., Pastores G.M.;
RT   "Identification and expression of acid beta-glucosidase mutations
RT   causing severe type 1 and neurologic type 2 Gaucher disease in non-
RT   Jewish patients.";
RL   J. Clin. Invest. 99:2530-2537(1997).
RN   [51]
RP   VARIANTS GD VAL-228; ILE-252; GLY-405; HIS-448; GLN-452; PRO-483 AND
RP   CYS-535.
RX   MEDLINE=97215205; PubMed=9061570; DOI=10.1023/A:1005313724361;
RA   Ida H., Rennert O.M., Kawame H., Maekawa K., Eto Y.;
RT   "Mutation prevalence among 47 unrelated Japanese patients with Gaucher
RT   disease: identification of four novel mutations.";
RL   J. Inherit. Metab. Dis. 20:67-73(1997).
RN   [52]
RP   VARIANT PSEUDO-GAUCHER HIS-448.
RX   MEDLINE=97192182; PubMed=9040001;
RA   Uyama E., Uchino M., Ida H., Eto Y., Owada M.;
RT   "D409H/D409H genotype in Gaucher-like disease.";
RL   J. Med. Genet. 34:175-175(1997).
RN   [53]
RP   VARIANTS GD LEU-146; LEU-198; THR-380; ASN-405 AND ARG-432.
RX   MEDLINE=98213117; PubMed=9554454; DOI=10.1159/000040815;
RA   Demina A., Beutler E.;
RT   "Six new Gaucher disease mutations.";
RL   Acta Haematol. 99:80-82(1998).
RN   [54]
RP   VARIANTS GD.
RX   MEDLINE=98349965; PubMed=9683600; DOI=10.1086/301969;
RA   Germain D.P., Puech J.-P., Caillaud C., Kahn A., Poenaru L.;
RT   "Exhaustive screening of the acid beta-glucosidase gene, by
RT   fluorescence-assisted mismatch analysis using universal primers:
RT   mutation profile and genotype/phenotype correlations in Gaucher
RT   disease.";
RL   Am. J. Hum. Genet. 63:415-427(1998).
RN   [55]
RP   VARIANT GD2 TYR-513.
RX   MEDLINE=98299544; PubMed=9637431;
RX   DOI=10.1002/(SICI)1096-8628(19980616)78:1<92::AID-AJMG19>3.3.CO;2-8;
RA   Choy F.Y.M., Humphries M.L., Ben-Yoseph Y.;
RT   "Gaucher type 2 disease: identification of a novel transversion
RT   mutation in a French-Irish patient.";
RL   Am. J. Med. Genet. 78:92-93(1998).
RN   [56]
RP   VARIANTS GD.
RX   MEDLINE=98184932; PubMed=9516376; DOI=10.1006/bcmd.1998.0165;
RA   Beutler E., Gelbart T.;
RT   "Hematologically important mutations: Gaucher disease.";
RL   Blood Cells Mol. Dis. 24:2-8(1998).
RN   [57]
RP   VARIANTS GD2 LYS-80; CYS-170 AND PRO-483.
RX   MEDLINE=99097160; PubMed=9851895; DOI=10.1006/bcmd.1998.0210;
RA   Sinclair G., Choy F.Y.M., Humphries L.;
RT   "A novel complex allele and two new point mutations in type 2 (acute
RT   neuronopathic) Gaucher disease.";
RL   Blood Cells Mol. Dis. 24:420-427(1998).
RN   [58]
RP   VARIANT GD GLY-392.
RX   MEDLINE=98312786; PubMed=9650766;
RA   Parenti G., Filocamo M., Titomanlio L., Rizzolo G., Silvestro E.,
RA   Perretti A., Gatti R., Andria G.;
RT   "A novel mutation of the beta-glucocerebrosidase gene associated with
RT   neurologic manifestations in three sibs.";
RL   Clin. Genet. 53:281-285(1998).
RN   [59]
RP   VARIANTS GD GLU-152; PRO-173; GLU-428; LEU-430; ILE-431 AND HIS-451.
RX   MEDLINE=98213468; PubMed=9554746;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:4<295::AID-HUMU7>3.3.CO;2-Y;
RA   Cormand B., Grinberg D., Gort L., Chabas A., Vilageliu L.;
RT   "Molecular analysis and clinical findings in the Spanish Gaucher
RT   disease population: putative haplotype of the N370S ancestral
RT   chromosome.";
RL   Hum. Mutat. 11:295-305(1998).
RN   [60]
RP   VARIANTS GD1 GLY-230 AND SER-409.
RX   PubMed=10206680;
RX   DOI=10.1002/(SICI)1098-1004(1998)11:5<411::AID-HUMU13>3.3.CO;2-O;
RA   Choy F.Y.M., Humphries M.L., Ben-Yoseph Y.;
RT   "A novel mutation (V191G) in a German-British type 1 Gaucher disease
RT   patient.";
RL   Hum. Mutat. 11:411-412(1998).
RN   [61]
RP   VARIANTS GD1 SER-409 AND LEU-440.
RX   MEDLINE=99270472; PubMed=10340647;
RX   DOI=10.1002/(SICI)1096-8628(19990604)84:4<334::AID-AJMG5>3.3.CO;2-G;
RA   Wasserstein M.P., Martignetti J.A., Zeitlin R., Lumerman H.,
RA   Solomon M., Grace M.E., Desnick R.J.;
RT   "Type 1 Gaucher disease presenting with extensive mandibular lytic
RT   lesions: identification and expression of a novel acid beta-
RT   glucosidase mutation.";
RL   Am. J. Med. Genet. 84:334-339(1999).
RN   [62]
RP   VARIANTS GD ARG-241; CYS-244; ILE-252; HIS-448 AND PRO-483.
RX   MEDLINE=99287149; PubMed=10360404;
RX   DOI=10.1002/(SICI)1096-8628(19990611)84:5<484::AID-AJMG14>3.0.CO;2-W;
RA   Choy F.Y.M., Wong K., Shi H.P.;
RT   "Glucocerebrosidase mutations among Chinese neuronopathic and non-
RT   neuronopathic Gaucher disease patients.";
RL   Am. J. Med. Genet. 84:484-486(1999).
RN   [63]
RP   VARIANTS GD.
RX   MEDLINE=20201378; PubMed=10744424;
RA   Hodanov K., Hrebicek M., Cervenkov M., Mrzov L., Veprekov L.,
RA   Zemen J.;
RT   "Analysis of the beta-glucocerebrosidase gene in Czech and Slovak
RT   Gaucher patients: mutation profile and description of six novel mutant
RT   alleles.";
RL   Blood Cells Mol. Dis. 25:287-298(1999).
RN   [64]
RP   VARIANTS PERINATAL LETHAL GD ARG-350 AND PHE-437.
RX   MEDLINE=99281208; PubMed=10352942; DOI=10.1038/sj.ejhg.5200315;
RA   Stone D.L., van Diggelen O.P., de Klerk J.B.C., Gaillard J.L.J.,
RA   Niermeijer M.F., Willemsen R., Tayebi N., Sidransky E.;
RT   "Is the perinatal lethal form of Gaucher disease more common than
RT   classic type 2 Gaucher disease?";
RL   Eur. J. Hum. Genet. 7:505-509(1999).
RN   [65]
RP   VARIANTS GD PRO-173; TRP-234; SER-409; SER-416; HIS-448 AND PRO-483.
RX   MEDLINE=99374932; PubMed=10447266;
RX   DOI=10.1002/(SICI)1098-1004(1999)14:1<88::AID-HUMU16>3.0.CO;2-E;
RA   Sarria A.J., Giraldo P., Perez-Calvo J.I., Pocovi M.;
RT   "Detection of three rare (G377S, T134P and 1451delAC), and two novel
RT   mutations (G195W and Rec[1263del55;1342G>C]] in Spanish Gaucher
RT   disease patients.";
RL   Hum. Mutat. 14:88-88(1999).
RN   [66]
RP   VARIANTS GD TRP-87; ASN-118; THR-129; ASP-156; GLN-159; TRP-159;
RP   LEU-170; ILE-173; CYS-209; PRO-209; SER-227; THR-229; PRO-235;
RP   ARG-241; ILE-252; GLN-296; CYS-324; THR-380; MET-408; SER-409;
RP   SER-416; LEU-433; TYR-438; HIS-448; PRO-483 AND CYS-502, AND VARIANT
RP   LYS-365.
RX   PubMed=10796875; DOI=10.1086/302925;
RA   Koprivica V., Stone D.L., Park J.K., Callahan M., Frisch A.,
RA   Cohen I.J., Tayebi N., Sidransky E.;
RT   "Analysis and classification of 304 mutant alleles in patients with
RT   type 1 and type 3 Gaucher disease.";
RL   Am. J. Hum. Genet. 66:1777-1786(2000).
RN   [67]
RP   VARIANTS GD SER-55 AND HIS-448.
RX   PubMed=11992489; DOI=10.1002/ajmg.10385;
RA   Bodamer O.A.F., Church H.J., Cooper A., Wraith J.E., Scott C.R.,
RA   Scaglia F.;
RT   "Variant Gaucher disease characterized by dysmorphic features, absence
RT   of cardiovascular involvement, laryngospasm, and compound
RT   heterozygosity for a novel mutation (D409H/C16S).";
RL   Am. J. Med. Genet. 109:328-331(2002).
RN   [68]
RP   VARIANTS GD GLU-175; PRO-201; GLU-237; LEU-290 AND PHE-441.
RX   PubMed=11933202; DOI=10.1002/humu.9024;
RA   Orvisky E., Park J.K., Parker A., Walker J.M., Martin B.M.,
RA   Stubblefield B.K., Uyama E., Tayebi N., Sidransky E.;
RT   "The identification of eight novel glucocerebrosidase (GBA) mutations
RT   in patients with Gaucher disease.";
RL   Hum. Mutat. 19:458-459(2002).
RN   [69]
RP   VARIANTS GD THR-198; ARG-241; ARG-270; ILE-400 AND ARG-490.
RX   PubMed=12204005; DOI=10.1002/humu.9058;
RA   Filocamo M., Mazzotti R., Stroppiano M., Seri M., Giona F.,
RA   Parenti G., Regis S., Corsolini F., Zoboli S., Gatti R.;
RT   "Analysis of the glucocerebrosidase gene and mutation profile in 144
RT   Italian gaucher patients.";
RL   Hum. Mutat. 20:234-235(2002).
RN   [70]
RP   POSSIBLE INVOLVEMENT IN PARKINSON DISEASE.
RX   PubMed=12847165;
RA   Bembi B., Zambito Marsala S., Sidransky E., Ciana G., Carrozzi M.,
RA   Zorzon M., Martini C., Gioulis M., Pittis M.G., Capus L.;
RT   "Gaucher's disease with Parkinson's disease: clinical and pathological
RT   aspects.";
RL   Neurology 61:99-101(2003).
RN   [71]
RP   VARIANT GD SER-55.
RX   PubMed=15292921; DOI=10.1038/sj.ejhg.5201251;
RA   Church H.J., Cooper A., Stewart F., Thornton C.M., Wraith J.E.;
RT   "Homozygous loss of a cysteine residue in the glucocerebrosidase gene
RT   results in Gaucher's disease with a hydropic phenotype.";
RL   Eur. J. Hum. Genet. 12:975-978(2004).
RN   [72]
RP   CHARACTERIZATION OF VARIANT GD SER-409.
RX   PubMed=15826241; DOI=10.1042/BJ20050325;
RA   Salvioli R., Tatti M., Scarpa S., Moavero S.M., Ciaffoni F.,
RA   Felicetti F., Kaneski C.R., Brady R.O., Vaccaro A.M.;
RT   "The N370S (Asn370->Ser) mutation affects the capacity of
RT   glucosylceramidase to interact with anionic phospholipid-containing
RT   membranes and saposin C.";
RL   Biochem. J. 390:95-103(2005).
RN   [73]
RP   VARIANTS GD1 ASN-63; SER-158; TRP-159; CYS-170; LEU-221; GLU-230;
RP   ARG-241; GLN-294; CYS-324; SER-409; ASN-438; LEU-440; HIS-448;
RP   CYS-457; ASP-460; PRO-483 AND ARG-490, AND CHARACTERIZATION OF
RP   VARIANTS GD1 ASN-63; SER-158; LEU-221; GLU-230 AND ASP-460.
RX   PubMed=15605411; DOI=10.1002/humu.9301;
RA   Miocic S., Filocamo M., Dominissini S., Montalvo A.L., Vlahovicek K.,
RA   Deganuto M., Mazzotti R., Cariati R., Bembi B., Pittis M.G.;
RT   "Identification and functional characterization of five novel mutant
RT   alleles in 58 Italian patients with Gaucher disease type 1.";
RL   Hum. Mutat. 25:100-100(2005).
RN   [74]
RP   POSSIBLE INVOLVEMENT IN PARKINSON DISEASE.
RX   PubMed=16148263; DOI=10.1212/01.wnl.0000176987.47875.28;
RA   Aharon-Peretz J., Badarny S., Rosenbaum H., Gershoni-Baruch R.;
RT   "Mutations in the glucocerebrosidase gene and Parkinson disease:
RT   phenotype-genotype correlation.";
RL   Neurology 65:1460-1461(2005).
RN   [75]
RP   INVOLVEMENT OF VARIANT GD PRO-483 IN SUSCEPTIBILITY TO PARKINSON
RP   DISEASE.
RX   PubMed=17620502; DOI=10.1001/archneur.64.7.1056;
RA   Tan E.K., Tong J., Fook-Chong S., Yih Y., Wong M.C., Pavanni R.,
RA   Zhao Y.;
RT   "Glucocerebrosidase mutations and risk of Parkinson disease in Chinese
RT   patients.";
RL   Arch. Neurol. 64:1056-1058(2007).
RN   [76]
RP   INVOLVEMENT OF VARIANTS GD SER-409 AND PRO-483 IN SUSCEPTIBILITY TO
RP   PARKINSON DISEASE.
RX   PubMed=18332251; DOI=10.1001/archneurol.2007.68;
RA   Mata I.F., Samii A., Schneer S.H., Roberts J.W., Griffith A.,
RA   Leis B.C., Schellenberg G.D., Sidransky E., Bird T.D., Leverenz J.B.,
RA   Tsuang D., Zabetian C.P.;
RT   "Glucocerebrosidase gene mutations: a risk factor for Lewy body
RT   disorders.";
RL   Arch. Neurol. 65:379-382(2008).
RN   [77]
RP   INVOLVEMENT OF VARIANTS GD SER-409 AND PRO-483 IN SUSCEPTIBILITY TO
RP   PARKINSON DISEASE.
RX   PubMed=19846850; DOI=10.1056/NEJMoa0901281;
RA   Sidransky E., Nalls M.A., Aasly J.O., Aharon-Peretz J., Annesi G.,
RA   Barbosa E.R., Bar-Shira A., Berg D., Bras J., Brice A., Chen C.M.,
RA   Clark L.N., Condroyer C., De Marco E.V., Durr A., Eblan M.J., Fahn S.,
RA   Farrer M.J., Fung H.C., Gan-Or Z., Gasser T., Gershoni-Baruch R.,
RA   Giladi N., Griffith A., Gurevich T., Januario C., Kropp P., Lang A.E.,
RA   Lee-Chen G.J., Lesage S., Marder K., Mata I.F., Mirelman A.,
RA   Mitsui J., Mizuta I., Nicoletti G., Oliveira C., Ottman R.,
RA   Orr-Urtreger A., Pereira L.V., Quattrone A., Rogaeva E., Rolfs A.,
RA   Rosenbaum H., Rozenberg R., Samii A., Samaddar T., Schulte C.,
RA   Sharma M., Singleton A., Spitz M., Tan E.K., Tayebi N., Toda T.,
RA   Troiano A.R., Tsuji S., Wittstock M., Wolfsberg T.G., Wu Y.R.,
RA   Zabetian C.P., Zhao Y., Ziegler S.G.;
RT   "Multicenter analysis of glucocerebrosidase mutations in Parkinson's
RT   disease.";
RL   N. Engl. J. Med. 361:1651-1661(2009).
CC   -!- CATALYTIC ACTIVITY: D-glucosyl-N-acylsphingosine + H(2)O = D-
CC       glucose + N-acylsphingosine.
CC   -!- ENZYME REGULATION: Requires saposin-C and anionic phospholipids
CC       for activity.
CC   -!- SUBUNIT: Interacts with saposin-C. Interacts with SCARB2.
CC   -!- INTERACTION:
CC       O35114:Scarb2 (xeno); NbExp=1; IntAct=EBI-1564609, EBI-1564519;
CC   -!- SUBCELLULAR LOCATION: Lysosome membrane; Peripheral membrane
CC       protein; Lumenal side. Note=Interaction with saposin-C promotes
CC       membrane association. Targeting to lysosomes occurs through an
CC       alternative MPR-independent mechanism via SCARB2.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=3;
CC       Name=Long;
CC         IsoId=P04062-1; Sequence=Displayed;
CC         Note=Has a 39 residue signal sequence. The upstream initiation
CC         site produces two to three times as much protein as does the
CC         downstream initiation codon;
CC       Name=Short;
CC         IsoId=P04062-2; Sequence=VSP_018800;
CC         Note=Has a 19 residue signal sequence;
CC       Name=3;
CC         IsoId=P04062-3; Sequence=VSP_025216, VSP_025217, VSP_025218;
CC         Note=Produced by alternative splicing;
CC   -!- DISEASE: Defects in GBA are the cause of Gaucher disease (GD)
CC       [MIM:230800]; also known as glucocerebrosidase deficiency. GD is
CC       the most prevalent lysosomal storage disease, characterized by
CC       accumulation of glucosylceramide in the reticulo-endothelial
CC       system. Different clinical forms are recognized depending on the
CC       presence (neuronopathic forms) or absence of central nervous
CC       system involvement, severity and age of onset.
CC   -!- DISEASE: Defects in GBA are the cause of Gaucher disease type 1
CC       (GD1) [MIM:230800]; also known as adult non-neuronopathic Gaucher
CC       disease. GD1 is characterized by hepatosplenomegaly with
CC       consequent anemia and thrombopenia, and bone involvement. The
CC       central nervous system is not involved.
CC   -!- DISEASE: Defects in GBA are the cause of Gaucher disease type 2
CC       (GD2) [MIM:230900]; also known as acute neuronopathic Gaucher
CC       disease. GD2 is the most severe form and is universally
CC       progressive and fatal. It manifests soon after birth, with death
CC       generally occurring before patients reach two years of age.
CC   -!- DISEASE: Defects in GBA are the cause of Gaucher disease type 3
CC       (GD3) [MIM:231000]; also known as subacute neuronopathic Gaucher
CC       disease. GD3 has central nervous manifestations.
CC   -!- DISEASE: Defects in GBA are the cause of Gaucher disease type 3C
CC       (GD3C) [MIM:231005]; also known as pseudo-Gaucher disease or
CC       Gaucher-like disease.
CC   -!- DISEASE: Defects in GBA are the cause of Gaucher disease perinatal
CC       lethal (GDPL) [MIM:608013]. It is a distinct form of Gaucher
CC       disease type 2, characterized by fetal onset. Hydrops fetalis, in
CC       utero fetal death and neonatal distress are prominent features.
CC       When hydrops is absent, neurologic involvement begins in the first
CC       week and leads to death within 3 months. Hepatosplenomegaly is a
CC       major sign, and is associated with ichthyosis, arthrogryposis, and
CC       facial dysmorphism.
CC   -!- DISEASE: Note=Perinatal lethal Gaucher disease is associated with
CC       non-immune hydrops fetalis, a generalized edema of the fetus with
CC       fluid accumulation in the body cavities due to non-immune causes.
CC       Non-immune hydrops fetalis is not a diagnosis in itself but a
CC       symptom, a feature of many genetic disorders, and the end-stage of
CC       a wide variety of disorders.
CC   -!- DISEASE: Defects in GBA contribute to susceptibility to Parkinson
CC       disease (PARK) [MIM:168600]. A complex neurodegenerative disorder
CC       characterized by bradykinesia, resting tremor, muscular rigidity
CC       and postural instability. Additional features are characteristic
CC       postural abnormalities, dysautonomia, dystonic cramps, and
CC       dementia. The pathology of Parkinson disease involves the loss of
CC       dopaminergic neurons in the substantia nigra and the presence of
CC       Lewy bodies (intraneuronal accumulations of aggregated proteins),
CC       in surviving neurons in various areas of the brain. The disease is
CC       progressive and usually manifests after the age of 50 years,
CC       although early-onset cases (before 50 years) are known. The
CC       majority of the cases are sporadic suggesting a multifactorial
CC       etiology based on environmental and genetic factors. However, some
CC       patients present with a positive family history for the disease.
CC       Familial forms of the disease usually begin at earlier ages and
CC       are associated with atypical clinical features.
CC   -!- PHARMACEUTICAL: Available under the names Ceredase and Cerezyme
CC       (Genzyme). Used to treat Gaucher's disease.
CC   -!- SIMILARITY: Belongs to the glycosyl hydrolase 30 family.
CC   -!- WEB RESOURCE: Name=Ceredase; Note=Clinical information on
CC       Ceredase;
CC       URL="http://www.genzyme.com/prodserv/specialty_therapeutics/ceredase/";
CC   -!- WEB RESOURCE: Name=Cerezyme; Note=Clinical information on
CC       Cerezyme;
CC       URL="http://www.genzyme.com/prodserv/specialty_therapeutics/cerezyme/";
CC   -!- WEB RESOURCE: Name=GeneReviews;
CC       URL="http://www.ncbi.nlm.nih.gov/sites/GeneTests/lab/gene/GBA";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M16328; AAA35873.1; -; mRNA.
DR   EMBL; K02920; AAA35877.1; -; mRNA.
DR   EMBL; J03059; AAC63056.1; -; Genomic_DNA.
DR   EMBL; D13286; BAA02545.1; -; mRNA.
DR   EMBL; D13287; BAA02546.1; -; mRNA.
DR   EMBL; AF023268; AAC51820.1; -; Genomic_DNA.
DR   EMBL; AK291911; BAF84600.1; -; mRNA.
DR   EMBL; AL713999; CAI95090.1; -; Genomic_DNA.
DR   EMBL; BC003356; AAH03356.1; -; mRNA.
DR   EMBL; M19285; AAA35880.1; -; mRNA.
DR   EMBL; M18916; AAA35878.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; M18917; AAA35879.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; M20248; AAA35874.1; -; Genomic_DNA.
DR   EMBL; M20282; AAA35876.1; -; Genomic_DNA.
DR   IPI; IPI00021807; -.
DR   IPI; IPI00759616; -.
DR   IPI; IPI00845473; -.
DR   PIR; A94068; EUHUGC.
DR   PIR; I52980; I52980.
DR   PIR; I67792; I67792.
DR   RefSeq; NP_000148.2; NM_000157.3.
DR   RefSeq; NP_001005741.1; NM_001005741.2.
DR   RefSeq; NP_001005742.1; NM_001005742.2.
DR   UniGene; Hs.282997; -.
DR   UniGene; Hs.719930; -.
DR   PDB; 1OGS; X-ray; 2.00 A; A/B=40-536.
DR   PDB; 1Y7V; X-ray; 2.40 A; A/B=40-536.
DR   PDB; 2F61; X-ray; 2.50 A; A/B=40-536.
DR   PDB; 2J25; X-ray; 2.90 A; A/B=40-536.
DR   PDB; 2NSX; X-ray; 2.11 A; A/B/C/D=40-536.
DR   PDB; 2NT0; X-ray; 1.79 A; A/B/C/D=40-536.
DR   PDB; 2NT1; X-ray; 2.30 A; A/B/C/D=40-536.
DR   PDB; 2V3D; X-ray; 1.96 A; A/B=40-536.
DR   PDB; 2V3E; X-ray; 2.00 A; A/B=40-536.
DR   PDB; 2V3F; X-ray; 1.95 A; A/B=40-536.
DR   PDB; 2VT0; X-ray; 2.15 A; A/B=40-536.
DR   PDB; 2WCG; X-ray; 2.30 A; A/B=40-536.
DR   PDB; 2WKL; X-ray; 2.70 A; A/B=40-536.
DR   PDB; 2XWD; X-ray; 2.66 A; A/B=40-536.
DR   PDB; 2XWE; X-ray; 2.31 A; A/B=40-536.
DR   PDB; 3GXD; X-ray; 2.50 A; A/B/C/D=40-536.
DR   PDB; 3GXF; X-ray; 2.40 A; A/B/C/D=40-536.
DR   PDB; 3GXI; X-ray; 1.84 A; A/B/C/D=40-536.
DR   PDB; 3GXM; X-ray; 2.20 A; A/B/C/D=40-536.
DR   PDB; 3KE0; X-ray; 2.70 A; A/B=40-536.
DR   PDB; 3KEH; X-ray; 2.80 A; A/B=40-536.
DR   PDBsum; 1OGS; -.
DR   PDBsum; 1Y7V; -.
DR   PDBsum; 2F61; -.
DR   PDBsum; 2J25; -.
DR   PDBsum; 2NSX; -.
DR   PDBsum; 2NT0; -.
DR   PDBsum; 2NT1; -.
DR   PDBsum; 2V3D; -.
DR   PDBsum; 2V3E; -.
DR   PDBsum; 2V3F; -.
DR   PDBsum; 2VT0; -.
DR   PDBsum; 2WCG; -.
DR   PDBsum; 2WKL; -.
DR   PDBsum; 2XWD; -.
DR   PDBsum; 2XWE; -.
DR   PDBsum; 3GXD; -.
DR   PDBsum; 3GXF; -.
DR   PDBsum; 3GXI; -.
DR   PDBsum; 3GXM; -.
DR   PDBsum; 3KE0; -.
DR   PDBsum; 3KEH; -.
DR   ProteinModelPortal; P04062; -.
DR   SMR; P04062; 40-536.
DR   IntAct; P04062; 3.
DR   MINT; MINT-3004354; -.
DR   STRING; P04062; -.
DR   Allergome; 8244; Hom s Glucocerebrosidase.
DR   CAZy; GH30; Glycoside Hydrolase Family 30.
DR   PhosphoSite; P04062; -.
DR   DMDM; 55584151; -.
DR   PRIDE; P04062; -.
DR   DNASU; 2629; -.
DR   Ensembl; ENST00000327247; ENSP00000314508; ENSG00000177628.
DR   Ensembl; ENST00000368373; ENSP00000357357; ENSG00000177628.
DR   Ensembl; ENST00000402928; ENSP00000385813; ENSG00000177628.
DR   Ensembl; ENST00000427500; ENSP00000402577; ENSG00000177628.
DR   Ensembl; ENST00000428024; ENSP00000397986; ENSG00000177628.
DR   GeneID; 2629; -.
DR   KEGG; hsa:2629; -.
DR   UCSC; uc001fjh.1; human.
DR   CTD; 2629; -.
DR   GeneCards; GC01M155204; -.
DR   HGNC; HGNC:4177; GBA.
DR   HPA; HPA006667; -.
DR   MIM; 168600; phenotype.
DR   MIM; 230800; phenotype.
DR   MIM; 230900; phenotype.
DR   MIM; 231000; phenotype.
DR   MIM; 231005; phenotype.
DR   MIM; 606463; gene.
DR   MIM; 608013; phenotype.
DR   neXtProt; NX_P04062; -.
DR   Orphanet; 2072; Gaucher disease - ophthalmoplegia - cardiovascular calcification.
DR   Orphanet; 77259; Gaucher disease type 1.
DR   Orphanet; 85212; Perinatal-lethal Gaucher disease.
DR   eggNOG; COG5520; -.
DR   GeneTree; ENSGT00390000009464; -.
DR   HOVERGEN; HBG002285; -.
DR   InParanoid; P04062; -.
DR   KO; K01201; -.
DR   OMA; VEAFPEK; -.
DR   OrthoDB; EOG43XV3S; -.
DR   PhylomeDB; P04062; -.
DR   BRENDA; 3.2.1.45; 2681.
DR   Reactome; REACT_111217; Metabolism.
DR   DrugBank; DB00088; Alglucerase.
DR   DrugBank; DB00053; Imiglucerase.
DR   NextBio; 10357; -.
DR   Bgee; P04062; -.
DR   CleanEx; HS_GBA; -.
DR   CleanEx; HS_GC; -.
DR   Genevestigator; P04062; -.
DR   GermOnline; ENSG00000177628; Homo sapiens.
DR   GO; GO:0043202; C:lysosomal lumen; ISS:BHF-UCL.
DR   GO; GO:0005765; C:lysosomal membrane; ISS:BHF-UCL.
DR   GO; GO:0043169; F:cation binding; IEA:InterPro.
DR   GO; GO:0004348; F:glucosylceramidase activity; IDA:BHF-UCL.
DR   GO; GO:0005102; F:receptor binding; ISS:BHF-UCL.
DR   GO; GO:0005975; P:carbohydrate metabolic process; IEA:InterPro.
DR   GO; GO:0008219; P:cell death; IEA:UniProtKB-KW.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; IMP:BHF-UCL.
DR   GO; GO:0046513; P:ceramide biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0006680; P:glucosylceramide catabolic process; IMP:BHF-UCL.
DR   GO; GO:0007040; P:lysosome organization; IEA:InterPro.
DR   GO; GO:0050728; P:negative regulation of inflammatory response; IC:BHF-UCL.
DR   GO; GO:0032715; P:negative regulation of interleukin-6 production; IDA:BHF-UCL.
DR   GO; GO:0043407; P:negative regulation of MAP kinase activity; IMP:BHF-UCL.
DR   GO; GO:0035307; P:positive regulation of protein dephosphorylation; IMP:BHF-UCL.
DR   GO; GO:0046512; P:sphingosine biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0023021; P:termination of signal transduction; IMP:BHF-UCL.
DR   InterPro; IPR013780; Glyco_hydro_13_b.
DR   InterPro; IPR001139; Glyco_hydro_30.
DR   InterPro; IPR013781; Glyco_hydro_subgr_catalytic.
DR   InterPro; IPR017853; Glycoside_hydrolase_SF.
DR   Gene3D; G3DSA:2.60.40.1180; Glyco_hydro_13_b; 1.
DR   Gene3D; G3DSA:3.20.20.80; Glyco_hydro_cat; 1.
DR   PANTHER; PTHR11069; Glyco_hydro_30; 1.
DR   Pfam; PF02055; Glyco_hydro_30; 1.
DR   PRINTS; PR00843; GLHYDRLASE30.
DR   SUPFAM; SSF51445; Glyco_hydro_cat; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative splicing;
KW   Complete proteome; Direct protein sequencing; Disease mutation;
KW   Disulfide bond; Gaucher disease; Glycoprotein; Glycosidase; Hydrolase;
KW   Ichthyosis; Lipid metabolism; Lysosome; Membrane; Neurodegeneration;
KW   Parkinson disease; Parkinsonism; Pharmaceutical; Polymorphism;
KW   Reference proteome; Signal; Sphingolipid metabolism.
FT   SIGNAL        1     39       In isoform Long.
FT   SIGNAL       21     39       In isoform Short.
FT   CHAIN        40    536       Glucosylceramidase.
FT                                /FTId=PRO_0000012177.
FT   ACT_SITE    274    274       Proton donor.
FT   ACT_SITE    379    379       Nucleophile.
FT   CARBOHYD     58     58       N-linked (GlcNAc...).
FT   CARBOHYD     98     98       N-linked (GlcNAc...).
FT   CARBOHYD    185    185       N-linked (GlcNAc...).
FT   CARBOHYD    309    309       N-linked (GlcNAc...).
FT   CARBOHYD    501    501       N-linked (GlcNAc...) (Potential).
FT   DISULFID     43     55
FT   DISULFID     57     62
FT   VAR_SEQ       1    161       Missing (in isoform 3).
FT                                /FTId=VSP_025216.
FT   VAR_SEQ       1     20       Missing (in isoform Short).
FT                                /FTId=VSP_018800.
FT   VAR_SEQ     422    423       LA -> PS (in isoform 3).
FT                                /FTId=VSP_025217.
FT   VAR_SEQ     425    536       Missing (in isoform 3).
FT                                /FTId=VSP_025218.
FT   VARIANT      46     46       K -> E (in a patient with Parkinson
FT                                disease).
FT                                /FTId=VAR_063066.
FT   VARIANT      54     54       V -> L (in GD).
FT                                /FTId=VAR_003255.
FT   VARIANT      55     55       C -> S (in GD; neuronopathic and
FT                                perinatal lethal forms; loss of
FT                                activity).
FT                                /FTId=VAR_032394.
FT   VARIANT      63     63       D -> N (in GD1; very low activity).
FT                                /FTId=VAR_032395.
FT   VARIANT      76     76       F -> V (in GD).
FT                                /FTId=VAR_003256.
FT   VARIANT      80     80       E -> K (in GD2; dbSNP:rs1141808).
FT                                /FTId=VAR_009033.
FT   VARIANT      82     82       T -> I (in GD).
FT                                /FTId=VAR_003257.
FT   VARIANT      85     85       G -> E (in GD).
FT                                /FTId=VAR_003258.
FT   VARIANT      87     87       R -> Q (in GD; 20% of normal activity).
FT                                /FTId=VAR_032197.
FT   VARIANT      87     87       R -> W (in GD; mild; dbSNP:rs1141814).
FT                                /FTId=VAR_003259.
FT   VARIANT      92     92       M -> T (in dbSNP:rs3205619).
FT                                /FTId=VAR_032396.
FT   VARIANT     118    118       K -> N (in GD; mild; 8% of normal
FT                                activity; increases susceptibility to
FT                                proteolytic degradation).
FT                                /FTId=VAR_003260.
FT   VARIANT     129    129       A -> T (in GD).
FT                                /FTId=VAR_032397.
FT   VARIANT     146    146       S -> L (in GD; type 2).
FT                                /FTId=VAR_009034.
FT   VARIANT     152    152       G -> E (in GD).
FT                                /FTId=VAR_003261.
FT   VARIANT     156    156       N -> D (in GD).
FT                                /FTId=VAR_032398.
FT   VARIANT     158    158       I -> S (in GD1; very low activity).
FT                                /FTId=VAR_032399.
FT   VARIANT     158    158       I -> T (in GD).
FT                                /FTId=VAR_003262.
FT   VARIANT     159    159       R -> Q (in GD; type 2; 13% of normal
FT                                activity).
FT                                /FTId=VAR_003263.
FT   VARIANT     159    159       R -> W (in GD; severe).
FT                                /FTId=VAR_003264.
FT   VARIANT     161    161       P -> L (in GD; 16% of normal activity).
FT                                /FTId=VAR_032198.
FT   VARIANT     161    161       P -> S (in GD; mild).
FT                                /FTId=VAR_003265.
FT   VARIANT     162    162       M -> V (in GD; loss of activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                /FTId=VAR_032199.
FT   VARIANT     166    166       D -> V (in GD; 9% of normal activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                /FTId=VAR_032200.
FT   VARIANT     170    170       R -> C (in GD1 and GD2; also found in a
FT                                patient with Parkinson disease).
FT                                /FTId=VAR_009035.
FT   VARIANT     170    170       R -> L (in GD).
FT                                /FTId=VAR_009036.
FT   VARIANT     173    173       T -> I (in GD).
FT                                /FTId=VAR_032400.
FT   VARIANT     173    173       T -> P (in GD).
FT                                /FTId=VAR_003266.
FT   VARIANT     175    175       A -> E (in GD).
FT                                /FTId=VAR_032401.
FT   VARIANT     179    179       D -> H (in GD).
FT                                /FTId=VAR_003267.
FT   VARIANT     196    196       K -> Q (in GD; severe).
FT                                /FTId=VAR_003268.
FT   VARIANT     198    198       P -> L (in GD).
FT                                /FTId=VAR_009037.
FT   VARIANT     198    198       P -> T (in GD).
FT                                /FTId=VAR_032402.
FT   VARIANT     200    200       I -> N (in GD; 5% of normal activity).
FT                                /FTId=VAR_032201.
FT   VARIANT     200    200       I -> S (in GD).
FT                                /FTId=VAR_010059.
FT   VARIANT     201    201       H -> P (in GD).
FT                                /FTId=VAR_032403.
FT   VARIANT     209    209       R -> C (in GD).
FT                                /FTId=VAR_032404.
FT   VARIANT     209    209       R -> P (in GD).
FT                                /FTId=VAR_003269.
FT   VARIANT     213    213       L -> F (in GD; 12% of normal activity).
FT                                /FTId=VAR_032202.
FT   VARIANT     215    215       A -> D (in GD).
FT                                /FTId=VAR_003270.
FT   VARIANT     217    217       P -> S (in GD; type 2).
FT                                /FTId=VAR_003271.
FT   VARIANT     221    221       P -> L (in GD1; very low activity).
FT                                /FTId=VAR_032405.
FT   VARIANT     221    221       P -> T (in GD).
FT                                /FTId=VAR_003272.
FT   VARIANT     223    223       W -> R (in GD; gene conversion).
FT                                /FTId=VAR_003273.
FT   VARIANT     224    224       L -> F (in GD; 4% of normal activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                /FTId=VAR_032203.
FT   VARIANT     227    227       N -> K (in GD; gene conversion;
FT                                dbSNP:rs381418).
FT                                /FTId=VAR_003275.
FT   VARIANT     227    227       N -> S (in GD; type 2; dbSNP:rs364897).
FT                                /FTId=VAR_003274.
FT   VARIANT     228    228       G -> V (in GD).
FT                                /FTId=VAR_010060.
FT   VARIANT     229    229       A -> E (in GD; type 2).
FT                                /FTId=VAR_009038.
FT   VARIANT     229    229       A -> T (in GD).
FT                                /FTId=VAR_032406.
FT   VARIANT     230    230       V -> E (in GD1; very low activity).
FT                                /FTId=VAR_032407.
FT   VARIANT     230    230       V -> G (in GD1; gene conversion;
FT                                dbSNP:rs381427).
FT                                /FTId=VAR_003276.
FT   VARIANT     232    232       G -> E (in GD; also found in a patient
FT                                with Parkinson disease; 7% of normal
FT                                activity).
FT                                /FTId=VAR_032204.
FT   VARIANT     234    234       G -> E (in GD; severe).
FT                                /FTId=VAR_003277.
FT   VARIANT     234    234       G -> W (in GD).
FT                                /FTId=VAR_009039.
FT   VARIANT     235    235       S -> P (in GD; type 2; gene conversion;
FT                                dbSNP:rs1064644).
FT                                /FTId=VAR_003278.
FT   VARIANT     237    237       K -> E (in GD; severe; loss of activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                /FTId=VAR_032205.
FT   VARIANT     241    241       G -> E (in GD).
FT                                /FTId=VAR_010061.
FT   VARIANT     241    241       G -> R (in GD; type 1 and type 2; gene
FT                                conversion).
FT                                /FTId=VAR_003279.
FT   VARIANT     244    244       Y -> C (in GD).
FT                                /FTId=VAR_010062.
FT   VARIANT     251    251       Y -> H (in GD).
FT                                /FTId=VAR_003280.
FT   VARIANT     252    252       F -> I (in GD; type 2; gene conversion;
FT                                dbSNP:rs381737).
FT                                /FTId=VAR_003281.
FT   VARIANT     255    255       F -> Y (in GD; mild).
FT                                /FTId=VAR_003282.
FT   VARIANT     270    270       T -> R (in GD).
FT                                /FTId=VAR_032408.
FT   VARIANT     276    276       S -> P (in GD).
FT                                /FTId=VAR_003283.
FT   VARIANT     290    290       F -> L (in GD; perinatal lethal form).
FT                                /FTId=VAR_032409.
FT   VARIANT     294    294       H -> Q (in GD1; also found in Gaucher
FT                                disease type 2).
FT                                /FTId=VAR_009040.
FT   VARIANT     296    296       R -> Q (in GD; type 2; also found in a
FT                                patient with Parkinson disease).
FT                                /FTId=VAR_003284.
FT   VARIANT     298    298       F -> L (in GD; type 2; 4% of normal
FT                                activity).
FT                                /FTId=VAR_009041.
FT   VARIANT     303    303       L -> I (in GD; 5% of normal activity).
FT                                /FTId=VAR_032206.
FT   VARIANT     304    304       G -> D (in GD).
FT                                /FTId=VAR_010063.
FT   VARIANT     305    305       P -> R (in GD; mild).
FT                                /FTId=VAR_003285.
FT   VARIANT     310    310       S -> G (in dbSNP:rs1057942).
FT                                /FTId=VAR_032410.
FT   VARIANT     310    310       S -> N (in GD; less than 5% of normal
FT                                activity).
FT                                /FTId=VAR_010064.
FT   VARIANT     324    324       R -> C (in GD; type 1).
FT                                /FTId=VAR_003286.
FT   VARIANT     324    324       R -> H (in GD; type 2).
FT                                /FTId=VAR_009042.
FT   VARIANT     328    328       P -> L (in GD; mild).
FT                                /FTId=VAR_003287.
FT   VARIANT     342    342       K -> I (in GD).
FT                                /FTId=VAR_003288.
FT   VARIANT     343    343       Y -> C (in GD; type 2; 16% of normal
FT                                activity; increases susceptibility to
FT                                proteolytic degradation).
FT                                /FTId=VAR_009043.
FT   VARIANT     348    348       A -> V (in GD).
FT                                /FTId=VAR_003289.
FT   VARIANT     350    350       H -> R (in perinatal lethal GD).
FT                                /FTId=VAR_009044.
FT   VARIANT     351    351       W -> C (in GD; mild).
FT                                /FTId=VAR_003290.
FT   VARIANT     352    352       Y -> H (in GD).
FT                                /FTId=VAR_003291.
FT   VARIANT     354    354       D -> H (in GD).
FT                                /FTId=VAR_003292.
FT   VARIANT     357    357       A -> D (in GD).
FT                                /FTId=VAR_003293.
FT   VARIANT     362    362       T -> I (in GD; 6% of normal activity).
FT                                /FTId=VAR_003294.
FT   VARIANT     363    363       L -> P (in GD).
FT                                /FTId=VAR_003295.
FT   VARIANT     364    364       G -> R (in GD; type 2).
FT                                /FTId=VAR_003296.
FT   VARIANT     365    365       E -> K (in GD; mild; 42% of normal
FT                                activity; dbSNP:rs2230288).
FT                                /FTId=VAR_003297.
FT   VARIANT     368    368       R -> H (in dbSNP:rs1064648).
FT                                /FTId=VAR_032411.
FT   VARIANT     380    380       A -> T (in GD).
FT                                /FTId=VAR_009045.
FT   VARIANT     381    381       C -> G (in GD; type 2; loss of activity).
FT                                /FTId=VAR_003298.
FT   VARIANT     388    388       E -> K (in GD; 12% of normal activity).
FT                                /FTId=VAR_032207.
FT   VARIANT     391    391       V -> L (in GD).
FT                                /FTId=VAR_010065.
FT   VARIANT     392    392       R -> G (in GD).
FT                                /FTId=VAR_010066.
FT   VARIANT     392    392       R -> W (in GD; 5% of normal activity).
FT                                /FTId=VAR_032208.
FT   VARIANT     398    398       R -> Q (in GD; mild).
FT                                /FTId=VAR_003299.
FT   VARIANT     400    400       M -> I (in GD).
FT                                /FTId=VAR_032412.
FT   VARIANT     402    402       Y -> C (in GD; 8% of normal activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                /FTId=VAR_032209.
FT   VARIANT     403    403       S -> T (in GD; mild).
FT                                /FTId=VAR_003300.
FT   VARIANT     405    405       S -> G (in GD).
FT                                /FTId=VAR_010067.
FT   VARIANT     405    405       S -> N (in GD).
FT                                /FTId=VAR_009046.
FT   VARIANT     408    408       T -> M (in GD; dbSNP:rs2230289).
FT                                /FTId=VAR_003301.
FT   VARIANT     409    409       N -> S (in GD1; common mutation;
FT                                associated with susceptibility to
FT                                Parkinson disease; alters interaction
FT                                with saposin-C and membranes and thereby
FT                                reduces enzyme activity; mild).
FT                                /FTId=VAR_003302.
FT   VARIANT     410    410       L -> V (in GD; 15% of normal activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                /FTId=VAR_032210.
FT   VARIANT     414    414       V -> L (in GD; mild).
FT                                /FTId=VAR_010068.
FT   VARIANT     416    416       G -> S (in GD; mild).
FT                                /FTId=VAR_003303.
FT   VARIANT     417    417       W -> G (in GD).
FT                                /FTId=VAR_003304.
FT   VARIANT     419    419       D -> A (in GD; type 2; also found in a
FT                                patient with Parkinson disease).
FT                                /FTId=VAR_003305.
FT   VARIANT     419    419       D -> H (in GD; 4% of normal activity).
FT                                /FTId=VAR_032211.
FT   VARIANT     419    419       D -> N (in GD).
FT                                /FTId=VAR_003306.
FT   VARIANT     421    421       N -> K (in GD; 22% of normal activity).
FT                                /FTId=VAR_032212.
FT   VARIANT     426    426       P -> L (in GD).
FT                                /FTId=VAR_010069.
FT   VARIANT     428    428       G -> E (in GD; type 2).
FT                                /FTId=VAR_003307.
FT   VARIANT     429    429       G -> R (in GD; 17% of normal activity).
FT                                /FTId=VAR_032213.
FT   VARIANT     430    430       P -> L (in GD).
FT                                /FTId=VAR_003308.
FT   VARIANT     431    431       N -> I (in GD; type 2).
FT                                /FTId=VAR_003309.
FT   VARIANT     432    432       W -> R (in GD).
FT                                /FTId=VAR_009047.
FT   VARIANT     433    433       V -> L (in GD; severe; 12% of normal
FT                                activity).
FT                                /FTId=VAR_003310.
FT   VARIANT     435    435       N -> T (in GD1; mild).
FT                                /FTId=VAR_003311.
FT   VARIANT     436    436       F -> S (in GD; 6% of normal activity;
FT                                alters protein stability and increases
FT                                susceptibility to proteolytic
FT                                degradation).
FT                                /FTId=VAR_032214.
FT   VARIANT     437    437       V -> F (in perinatal lethal GD).
FT                                /FTId=VAR_009048.
FT   VARIANT     437    437       V -> L (in GD3).
FT                                /FTId=VAR_010070.
FT   VARIANT     438    438       D -> N (in GD; type 1 and type 2; 14% of
FT                                normal activity; increases susceptibility
FT                                to proteolytic degradation).
FT                                /FTId=VAR_003312.
FT   VARIANT     438    438       D -> Y (in GD).
FT                                /FTId=VAR_032413.
FT   VARIANT     440    440       P -> L (in GD1).
FT                                /FTId=VAR_010071.
FT   VARIANT     441    441       I -> F (in GD; type 3).
FT                                /FTId=VAR_032414.
FT   VARIANT     441    441       I -> T (in GD; mild).
FT                                /FTId=VAR_010072.
FT   VARIANT     448    448       D -> H (in GD; type 1 and type
FT                                neuronopathic; at homozygosity it causes
FT                                GD3C; also found in a patient with
FT                                Parkinson disease; gene conversion; very
FT                                low activity; alters protein stability;
FT                                dbSNP:rs1064651).
FT                                /FTId=VAR_003313.
FT   VARIANT     448    448       D -> V (in GD; severe; very low activity;
FT                                alters protein stability).
FT                                /FTId=VAR_003314.
FT   VARIANT     450    450       F -> I (in GD).
FT                                /FTId=VAR_010073.
FT   VARIANT     451    451       Y -> H (in GD).
FT                                /FTId=VAR_003315.
FT   VARIANT     452    452       K -> Q (in GD).
FT                                /FTId=VAR_010074.
FT   VARIANT     454    454       P -> R (in GD; type 2).
FT                                /FTId=VAR_003316.
FT   VARIANT     455    455       M -> V (in GD; loss of activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                /FTId=VAR_032215.
FT   VARIANT     456    456       F -> V (in GD).
FT                                /FTId=VAR_003317.
FT   VARIANT     457    457       Y -> C (in GD).
FT                                /FTId=VAR_003318.
FT   VARIANT     460    460       G -> D (in GD1; associated with R-490;
FT                                loss of activity).
FT                                /FTId=VAR_032415.
FT   VARIANT     464    464       K -> E (in GD; severe).
FT                                /FTId=VAR_003319.
FT   VARIANT     482    482       D -> N (in a patient with Parkinson
FT                                disease).
FT                                /FTId=VAR_063067.
FT   VARIANT     483    483       L -> P (in GD1 and GD2; common mutation;
FT                                associated with susceptibility to
FT                                Parkinson disease; gene conversion; very
FT                                low activity; alters protein stability).
FT                                /FTId=VAR_003321.
FT   VARIANT     483    483       L -> R (in GD; severe).
FT                                /FTId=VAR_003320.
FT   VARIANT     485    485       A -> P (in GD).
FT                                /FTId=VAR_003322.
FT   VARIANT     490    490       H -> R (in GD; type 1; associated with D-
FT                                460).
FT                                /FTId=VAR_032416.
FT   VARIANT     495    495       A -> P (in GD; gene conversion;
FT                                dbSNP:rs368060).
FT                                /FTId=VAR_003323.
FT   VARIANT     497    497       V -> L.
FT                                /FTId=VAR_063068.
FT   VARIANT     500    500       L -> P (in GD; 10% of normal activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                /FTId=VAR_032216.
FT   VARIANT     501    501       N -> K (in GD; type 2).
FT                                /FTId=VAR_009049.
FT   VARIANT     502    502       R -> C (in GD; 37% of normal activity;
FT                                also found in patients with Parkinson
FT                                disease).
FT                                /FTId=VAR_003324.
FT   VARIANT     502    502       R -> P (in GD; loss of activity;
FT                                increases susceptibility to proteolytic
FT                                degradation).
FT                                /FTId=VAR_032217.
FT   VARIANT     509    509       L -> P.
FT                                /FTId=VAR_003325.
FT   VARIANT     513    513       D -> Y (in GD2).
FT                                /FTId=VAR_009050.
FT   VARIANT     517    517       G -> S (in GD).
FT                                /FTId=VAR_003326.
FT   VARIANT     530    530       T -> I (in GD3).
FT                                /FTId=VAR_010075.
FT   VARIANT     535    535       R -> C (in GD; mild).
FT                                /FTId=VAR_003327.
FT   VARIANT     535    535       R -> H (in GD; mild).
FT                                /FTId=VAR_003328.
FT   MUTAGEN      43     43       C->S: Loss of activity.
FT   MUTAGEN      57     57       C->S: Loss of activity.
FT   MUTAGEN      62     62       C->S: Loss of activity.
FT   MUTAGEN     379    379       E->G: Decreases activity 1000-fold.
FT   CONFLICT    227    227       N -> R (in Ref. 5; BAA02546).
FT   CONFLICT    470    470       S -> I (in Ref. 15; AA sequence).
FT   CONFLICT    534    534       R -> H (in Ref. 1; AAA35873).
FT   STRAND       49     52
FT   STRAND       54     60
FT   STRAND       75     82
FT   STRAND       88     94
FT   STRAND       96     98
FT   STRAND      103    116
FT   STRAND      119    123
FT   HELIX       126    132
FT   HELIX       137    148
FT   TURN        150    153
FT   STRAND      157    163
FT   STRAND      166    170
FT   STRAND      177    179
FT   HELIX       190    193
FT   HELIX       196    206
FT   STRAND      212    218
FT   HELIX       222    224
FT   STRAND      229    233
FT   STRAND      235    238
FT   HELIX       243    261
FT   STRAND      267    271
FT   HELIX       277    279
FT   HELIX       292    301
FT   HELIX       303    308
FT   TURN        311    314
FT   STRAND      315    323
FT   HELIX       324    326
FT   HELIX       329    335
FT   HELIX       338    341
FT   STRAND      346    352
FT   HELIX       359    369
FT   STRAND      373    381
FT   HELIX       396    411
FT   STRAND      414    422
FT   STRAND      440    444
FT   HELIX       445    447
FT   STRAND      449    452
FT   HELIX       454    463
FT   STRAND      471    479
FT   STRAND      482    489
FT   STRAND      495    501
FT   STRAND      503    505
FT   STRAND      507    513
FT   TURN        514    516
FT   STRAND      517    523
FT   STRAND      527    533
SQ   SEQUENCE   536 AA;  59716 MW;  FA1E15684344A0E6 CRC64;
     MEFSSPSREE CPKPLSRVSI MAGSLTGLLL LQAVSWASGA RPCIPKSFGY SSVVCVCNAT
     YCDSFDPPTF PALGTFSRYE STRSGRRMEL SMGPIQANHT GTGLLLTLQP EQKFQKVKGF
     GGAMTDAAAL NILALSPPAQ NLLLKSYFSE EGIGYNIIRV PMASCDFSIR TYTYADTPDD
     FQLHNFSLPE EDTKLKIPLI HRALQLAQRP VSLLASPWTS PTWLKTNGAV NGKGSLKGQP
     GDIYHQTWAR YFVKFLDAYA EHKLQFWAVT AENEPSAGLL SGYPFQCLGF TPEHQRDFIA
     RDLGPTLANS THHNVRLLML DDQRLLLPHW AKVVLTDPEA AKYVHGIAVH WYLDFLAPAK
     ATLGETHRLF PNTMLFASEA CVGSKFWEQS VRLGSWDRGM QYSHSIITNL LYHVVGWTDW
     NLALNPEGGP NWVRNFVDSP IIVDITKDTF YKQPMFYHLG HFSKFIPEGS QRVGLVASQK
     NDLDAVALMH PDGSAVVVVL NRSSKDVPLT IKDPAVGFLE TISPGYSIHT YLWRRQ
//
